18 February 2002 00:00 [Source: PCE]
Synetix plans to develop an improved synthetic route for the
Synetix recently licensed the phosphine-based ligand for
enantioselective hydrogenation from its developers, Merck.
Denis Geffroy, commercial manager of Synetix Chiral Technologies,
said Synetix planned to develop a replicable, scalable and economic
route to the ligand in order to produce kilogramme quantities.
Synetix has been working on this for three months and has been
'making progress' on a better route, said Geffroy.
Additionally, Synetix will sub-license the ligand to third party
fine chemical and pharmaceutical companies. It is currently working
on a commercial project using the ligand with a commercial
Once the improved synthetic route for PhanePhos is developed,
Synetix plans to use the ligand in conjunction with its
Geffroy said the ligand could be fixed to the inorganic support
either cationically through a metal centre or covalently through a
linker molecule attached to the aromatic ring of the ligand.
Scientists at Johnson Matthey Catalysts and Chemicals Division and
the Center for Applied Catalysis (CAC) at Seton Hall University,
New Jersey, US, have joined forces to manufacture and commercialise
solid-supported homogeneous catalysts, in response to the dramatic
growth of chirality in the pharmaceutical, agrochemical, and fine
The anchored homogeneous catalyst systems involved in the
collaboration, which will be developed at the CAC, include metal
complexes with chiral or other ligands anchored to a solid
The partners will develop techniques for the large-scale
manufacture of these catalysts, and will explore potential
commercial applications for these systems.
IBM is to collaborate with Pharmacopeia subsidiary, Accelrys, on
technology to enable chemists and biologists to develop new drugs
faster, more efficiently, and at lower costs.
IBM and Accelrys will team up, with each company contributing key
technologies, to help pharmaceutical and biotechnology companies
and medical research centres improve their R&D operations and
shorten the development cycle for new drugs.
Diversa and Degussa have agreed to evaluate and commercialise
selected biocatalysts for speciality chemicals and pharmaceutical
fine chemical applications. Diversa will supply biocatalysts,
developed using its proprietary technologies, to Degussa's Project
House Biotechnology for evaluation and process development. Degussa
will pay an initial fee in order to access Diversa's biocatalysts
as well as additional fees associated with the commercial
development efforts. Degussa will also pay licence fees and
royalties on any products that are commercialised as part of the
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial
to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free
trial to ICIS Chemical Business.